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Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs Objective: A recent meta-analysis suggested that opioid substitution therapy (OST) increased uptake of antiretroviral treatment (ART) and HIV viral suppression. We modelled whether OST could improve the HIV prevention benefit achieved by ART among people who inject drugs (PWID).
Methods:
We modelled how introducing OST could improve the coverage of ART across a PWID population for different baseline ART coverage levels. Using existing data on how yearly HIV-transmission risk is related to HIV plasma viral load, changes in the level of viral suppression across the population were used to project the relative reduction in yearly HIV-transmission risk achieved by ART, with or without OST, compared with if there was no ART -defined here as the prevention effectiveness of ART.
Introduction
Injecting drug use is an important driver of HIV transmission in Eastern Europe, North America, and parts of Asia [1, 2] , and is increasing in many settings including East Africa [3] [4] [5] .
Although the use of antiretroviral treatment (ART) has improved the lives of those infected with HIV [6] [7] [8] [9] [10] and can dramatically reduce HIV transmission (by 96% among serodiscordant couples [11] ), access to treatment and treatment outcomes are frequently inferior among people who inject drugs (PWID) because of a range of factors Existing evidence suggests opioid substitution therapy (OST) can reduce the frequency of injecting drug use [16, 17] , halve the risk of HIV and hepatitis C virus acquisition among PWID [18, 19] , and reduce drugrelated mortality [20] . Evidence is also emerging that concurrent OST use can improve ART outcomes among PWID, including the uptake and retention on ART, and the level of treatment adherence and viral suppression, as synthesized in a recent meta-analysis [21] .
We used data from this meta-analysis to estimate the degree to which OST could increase the HIV prevention benefit of ART among PWID. We first compared the average HIV prevention protection achieved by ART among PWID on OST to PWID off OST, and then compared the average prevention protection achieved by ART at the population level with and without the introduction of OST. These population-level projections either assumed no change in ART coverage among PWID not on OST, or alternatively evaluated how the dynamic nature of PWID coming on and off OST could increase the coverage of ART among PWID off OST.
Methods
Definition of antiretroviral treatment prevention effectiveness We evaluate the HIV prevention protection provided by ART for a specific PWID subpopulation by estimating the degree to which the level of ART use in that subpopulation decreases the annual HIV transmission risk averaged across all HIV-infected PWID on and off ART. We denote this as the 'prevention effectiveness' of ART for that subpopulation, which depends both on the coverage of ART among HIV-infected PWID in that subpopulation and the degree to which ART decreases the yearly HIV transmission risk or infectivity of those PWID on ART, as determined by their decrease in viral load after initiating ART [22] .
Static estimation of benefits of opioid substitution therapy Assuming a certain coverage of ART among those not on OST, and level of viral suppression among those on ART, synthesized effect estimates from our meta-analysis [21] were used to estimate the increased ART coverage among those currently on OST and increased proportion virally suppressed among those on OST and ART. This did not utilize synthesized estimates for the effect of OSTon ART recruitment or retention [21] , but just estimates for its effect on increasing ART coverage among those on OST, with no change in ART coverage among those off OST. For those on ART that are virally suppressed or unsuppressed, estimates of their log difference in viral load compared with PWID not on ART were used to estimate the relative decrease in HIV infectivity achieved through ART. These calculations utilized an existing observed association between plasma viral load (PVL) and yearly HIV transmission risk in serodiscordant couples [22] . For different ART and OST intervention coverage combinations, estimates of the relative decrease in HIV infectivity were then averaged across the proportion virally suppressed or not for specific subgroups to produce and compare estimates of the prevention effectiveness of ART. We estimated the relative increase in the prevention effectiveness of ART for PWID on OST compared with PWID off OST, and at the population level for different OST coverage levels compared with if OST had not been introduced. See supplementary materials for more methodological details, http://links.lww.com/QAD/ B63.
Dynamic estimation of benefits of opioid substitution therapy A dynamic model of OST and ART recruitment and retention among HIV-infected PWID was developed. The model assumed PWID on OST have improved ART recruitment and retention. Through PWID transitioning on and off OST, this allowed improvements in ART uptake among PWID on OST to affect ART coverage levels among PWID not on OST. This contrasts with the static model, which assumed a heightened ART coverage only among PWID on OST. The dynamic model was used to reestimate the increase in ART coverage that could occur at the population level because of introducing OST, and the population-level prevention effectiveness of ART for different OST coverage levels compared with if OST had not been introduced.
The dynamic model stratifies HIV-infected PWID by ART (never, currently, or previously on ART) and OST (not on OST, short, or long-term OST) status. HIVpositive PWID join the model at a constant rate calibrated to give a population of 1 000 000 HIV-positive PWID before ART is scaled-up. We do not consider any dynamic effect of ART on the rate of new HIV-positive PWID because we are only interested in the short-term benefits of OST on ART outcomes. PWID leave the model because of non-HIV death or injecting cessation. ART-naive HIV-infected PWID also experience HIVrelated mortality, or can be recruited onto ART. When on ART, HIV-related mortality is reduced, but PWID can discontinue HIV treatment. PWID discontinuing ART can recruit back onto ART, but at a lower rate than ARTnaive PWID. Recruitment onto OST occurs independently of ART status. When initiated onto OST, PWID enter short-term OST, from which they either leave OST or transition to long-term OST. PWID generally leave long-term OST at a reduced rate. When on OST, recruitment onto ART is increased and attrition is reduced [21] . The schematic for the dynamic model is shown in Figure 1 and parameters defined in Table 1 , with model equations given in the supplementary materials, http://links.lww.com/QAD/B63.
Model parameterization
The models were parameterized using data from various sources (Table 1) . First, the meta-analysis [21] gave estimates for how being on OST improved the coverage of ART (static model), the rates of recruitment onto and retention on ART (dynamic model), and the proportion on ART that are virally suppressed (both models). The estimated baseline PVL among PWID off ART was obtained from the Antiretroviral Therapy Cohort Collaboration study [23] carried out among 5761 PWID in Europe and North America who initiated ART between 1996 and 2013. The same study gave estimates for the proportion of PWID not virally suppressed at 12 months after initiating ART, and the decrease in PVL from baseline for virally suppressed and unsuppressed PWID.
The dynamic model required additional data to parameterize the dynamics of OST and ART retention and mortality (Table 1) . A wide range was used for the combined rate of injecting cessation and non-HIV mortality (5-25% per year) because of uncertainty across settings [20, [24] [25] [26] . HIV-related mortality [27, 28] was assumed to reduce by 66-80% if on ART [29] [30] [31] [32] [33] .
Estimates for the baseline level of ART retention among PWID were derived from a pan-European study [34] , whereas ART recruitment rates were calibrated to give different baseline ART coverage levels.
Data for long-term attrition from OST are limited [35] .
To model long-term attrition from OST, we combined five international data sets which captured OST retention for over 1 year ( [36] [37] [38] [39] and Hickman unpublished). These data were used to give a range for the long-term retention of PWID on OST ( Figure S2 and S3, http:// links.lww.com/QAD/B63), which were sampled for subsequent model runs (supplementary materials for details, http://links.lww.com/QAD/B63). Uniform distribution ranges for each parameter are given in Table  1 . Lastly, OST recruitment rates were calibrated to give different OST coverage scenarios.
Model analyses: static model To incorporate uncertainty, 1000 parameter sets were randomly sampled from the static model parameter distributions given in Table 1 . For each sampled parameter set, and a wide range of baseline ART coverage levels (10-90% when not on OST), we estimated the absolute and relative increase in the prevention effectiveness of ART for PWID on OST compared with PWID not on OST. For different OST coverage levels (20, 40, 60 , and 80%), we then estimated how the population-level prevention effectiveness of ART increases compared with if OST was not introduced.
Model analyses: dynamic model For the dynamic model, all additional model parameters with uncertainty distributions in Table 1 were randomly sampled to give 1000 parameter sets. For each parameter set, the ART recruitment rate was first calibrated to give a range of steady baseline ART coverage scenarios (10-90%). Then, for each ART scenario, OSTwas introduced with different OST recruitment rates being used to give a range of steady OST coverage levels (20, 40, 60 , and 80%).
For each OST and ART coverage scenario, we projected the degree to which OST increased the overall coverage of ART, and ART coverage among PWID on OST compared with PWID off OST. The ART coverage estimates for PWID on and off OSTwere then combined with the sampled parameter sets for the static model (other than ART coverage parameters) to reestimate the degree to which OST increases the population-level prevention effectiveness of ART for different OST and ART coverage levels.
Uncertainty analysis
A linear regression analysis of covariance [40] was undertaken to determine which parameter uncertainties contribute most to variability in the dynamic model's projections. We considered the relative increase in the population-level prevention effectiveness of ART for the scenario where the coverage of OST and baseline ART (Fig. 3a) . If OST coverage is 40% instead of 60%, then this reduces to 17.5% (6.8-31.5%), 12.4% (5.1-22.6%) and 8.0% (3.5-15.9%) for the same baseline ART coverage levels. Although less relative benefit is achieved by OST at higher ART coverage levels, the absolute effects are similar as presented in the previous paragraph.
Dynamic model projections
In contrast to the static model, the dynamic model incorporates PWID transitioning on and off OST. Through including this effect, the dynamic model projects a greater (Fig. 4) Subsequently, the dynamic model also predicts that OST scale-up will result in greater increases in the populationlevel prevention effectiveness of ART (Fig. 3b) Fig. 3b and Table S1 , http://links.lww.com/ QAD/B63). This is about 60% more than was projected by the static model (Fig. 3a) .
Uncertainty analysis
Analysis of covariance analyses ( Figure S5 , http:// links.lww.com/QAD/B63) suggest that most variability Impact of opioid substitution therapy on ART Mukandavire et al. 1185 in the dynamic model's projections of the relative increase in population-level prevention effectiveness of ART because of OST is because of uncertainty in the increased ART recruitment rate among PWID on OST compared with PWID off OST (accounts for 74.7% of variability). Additional variability is because of uncertainty in the log decrease in viral load among unsuppressed PWID on ART compared with PWID not on ART (15.0%), the proportion virally suppressed for PWID on ART but not OST (2.3%), and the decreased ART attrition rate among PWID on OST compared with PWID off OST (2.5%).
Discussion
Our findings suggest that OST could markedly increase the HIV prevention benefit of ART for PWID. At the population level, moderate OST coverage (40%) could increase the prevention effectiveness of ART by about a quarter if the baseline ART coverage is low to moderate (20-40%) or about half of this if ART coverage is high (60%). This beneficial effect largely results from OST increasing the coverage of ART among those on OST, and as a by-product increasing the coverage of ART among those not on OST through PWID transitioning on and off OST. However, if OST scale-up does not increase ART coverage among PWID not on OST, then the degree to which OST improves the population-level prevention benefit of ART is halved, but is still important for low ART coverage levels (<40%) or at the individual level for all PWID on OST. It is likely that these indirect benefits of OST in improving the prevention benefit of ART could result in important gains in HIV infections averted (see supplementary materials, http://links.lww. com/QAD/B63), possibly comparable with the benefits achieved by OST through directly reducing injectionrelated HIV transmission risk.
Limitations
There are limitations to our projections. First, there was uncertainty around many model parameters such as the effect of OST on ART recruitment and coverage. Our modelling results were generally robust to these uncertainties, with only uncertainty in the factor increase in ART recruitment for PWID on OST compared with PWID off OST resulting in sizeable uncertainty in our projections. Improved data on this parameter is needed.
Other simplifying assumptions include the rate of non-HIV death and/or injecting cessation being the same for PWID on and off OST. Studies generally show that OST improves drug-related mortality [20] and may increase injecting cessation [41, 42] . Although important effects, it is unlikely that they will affect our results, as suggested by our uncertainty analysis and previous analyses [43] . Additionally, the dynamic model assumed that OST and ART attrition occurred independently of each other which resulted in the model projecting that OST scale-up could also increase ART coverage among PWID not on OST. However, although data is sparse, it is possible that both events could be linked, with ART attrition being more likely when PWID cease OST. This could be due to both treatments being dispensed alongside each other, or a common structural factor or event hindering further use of both services such as incarceration. If this were the case in specific settings, then the results of our static model could be closer to reality. For determining which model is most valid in a specific setting, it is important to understand the different reasons for PWID leaving OST and ART, and so the likelihood of the events being linked. Insights into this could also be aided by observing the degree to which OSTand ARTattrition at the individuallevel occurs over similar follow-up periods in observational studies of PWID on OST and ART [21] .
There is also uncertainty around the efficacy of ART for reducing injecting HIV transmission. Although it is likely that ART will reduce the risk of injection-related HIV transmission, because of large reductions in viral load, the actual efficacy is uncertain [44] . Although this would affect our estimates of the prevention benefit of ART, it should not affect the relative degree to which OST improves this, as suggested by our uncertainty analysis. Additionally, although limited data suggests parenteral HIV transmission risk may increase with heightened viral load [45] , no data exist on the precise relationship. Our analyses therefore relied on data from serodiscordant couple studies suggesting that heterosexual HIV transmission risk is strongly related to the logarithm of the PVL [22] . However, other analyses have suggested alternative relationships, with Fraser et al. [46] proposing a saturating effect at high viral loads; reassuringly our results are robust to this different assumption (see supplementary materials, http://links.lww.com/QAD/B63). Moreover, although HIV transmission risk among PWID is likely to depend on more complex behavioural and network factors than among serodiscordant couples, it should still be reasonable to assume that ART will similarly affect levels of HIV transmission risk as considered in this analysis.
The model used in this analysis only considered the shortterm benefits of OST in increasing the impact of ARTon yearly HIV transmission risk. Over time, any differences in transmission risk between two intervention scenarios could be amplified because of heightened reductions in HIV prevalence in the ART with OST scenario, and so our projections may be conservative. Conversely, the model assumed all HIV-infected PWID are equally likely to be on ART, and so did not account for the initial phase of HIV infection when individuals are unlikely to be on ART but will have elevated HIV infectivity [47] . Although this may reduce the prevention effectiveness of ART, it should have less effect on the degree to which OST improves the benefits achieved. The analysis also did not consider the direct prevention benefit of OST scaleup on HIV transmission, and so underestimates the overall benefits achieved from scaling-up OST. Future modelling should consider the longer term combined benefits of scaling-up OST and ART, while incorporating the synergies between these interventions.
Last, the projections of this model were primarily based on findings from a recent meta-analysis that synthesized evidence on the effects of OST use on different ART outcomes [21] . Although this should be considered a strength of the model analysis, weaknesses in the synthesized data sets, including the reliance on observational cohorts does raise concerns which could only be reduced through further data collection. However, future studies will still likely rely on observational cohorts, with their inherent weaknesses, because the other proven benefits of OST [18, 20, 48, 49] restrict the ability to randomize PWID onto OSTor not. Other weaknesses of the synthesized studies include little in-depth consideration of the reasons why PWID did not achieve optimal ARToutcomes, including viral suppression, and the likely reasons why OST improved these outcomes. Instead, current studies generally have just evaluated the overall effect of OSTon improving different ARToutcomes, and our model made the same simplifying assumption. It is important that future studies seek to understand the processes by which OST achieves a beneficial effect, and determine whether OST only acts on certain factors impeding optimal ARToutcomes. This would benefit the design of future interventions.
Comparison with other studies A recent systematic review found that OST can halve the risk of HIVacquisition among PWID [18] , and numerous modelling analyses have suggested that scaling up OST and/or ART among PWID could dramatically reduce HIV transmission [50] [51] [52] , and be cost-effective [53] [54] [55] . This is the first study to demonstrate that OST could improve the prevention benefits of ART.
Implications
Accumulating evidence suggests that OST could dramatically improve the cascade of care among HIVinfected PWID [21, 33, 56] , with modelling in this study further suggesting that these improvements could enhance the effectiveness of ART in reducing HIV transmission. These findings add to the evidence base for the multiple benefits of OST [57] [58] [59] [60] , and support strategies to integrate OSTwith HIV services to optimize the benefits achieved. Unfortunately, many countries have low OST coverage, or even forbid its provision [61, 62] , and PWID frequently have suboptimal coverage of ART [29] . Many of these countries have significant ongoing HIV epidemics or have experienced new HIV outbreaks [4, [63] [64] [65] [66] [67] [68] [69] . In these settings, the joint scale-up of OSTwith ART could have a substantial effect on HIV transmission and morbidity, and is likely to be highly costeffective [70] [71] [72] . However, to optimize the impact of OST a number of structural and policy barriers will have to be overcome to increase the uptake of OST and/or ART among PWID, including reducing the stigmatization of PWID in health settings and reducing the criminalization of drug use [73] .
